Published in Br Med J (Clin Res Ed) on February 20, 1982
Circadian rhythms in RA. Ann Rheum Dis (2003) 1.47
Neural immune pathways and their connection to inflammatory diseases. Arthritis Res Ther (2003) 1.40
The timing of glucocorticoid administration in rheumatoid arthritis. Ann Rheum Dis (1997) 1.33
Overnight variations in cortisol, interleukin 6, tumour necrosis factor alpha and other cytokines in people with rheumatoid arthritis. Ann Rheum Dis (2008) 1.19
Menstrual cyclicity of finger joint size and grip strength in patients with rheumatoid arthritis. Ann Rheum Dis (1983) 1.06
Rhythmic variations in pain, stiffness, and manual dexterity in hand osteoarthritis. Ann Rheum Dis (2002) 1.04
Circadian rhythm in pain, stiffness, and manual dexterity in rheumatoid arthritis: relation between discomfort and disability. Ann Rheum Dis (1991) 1.00
Circadian variation in biochemical assessments used to monitor rheumatoid arthritis. Ann Rheum Dis (1984) 0.99
Circadian rhythm of serum cytidine deaminase in patients with rheumatoid arthritis during rest and exercise. Ann Rheum Dis (1989) 0.97
Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis. Clin Exp Immunol (1993) 0.97
Pharmacokinetics and pharmacodynamics of methylprednisolone when administered at 8 am versus 4 pm. Clin Pharmacol Ther (1992) 0.90
Endogenous glucocorticoids modulate neutrophil migration and synovial P-selectin but not neutrophil phagocytic or oxidative function in experimental arthritis. Clin Exp Immunol (1998) 0.84
Free-running circadian rhythms of muscle strength, reaction time, and body temperature in totally blind people. Eur J Appl Physiol (2012) 0.83
Adenosine A2A receptor and TNF-α regulate the circadian machinery of the human monocytic THP-1 cells. Inflammation (2013) 0.78
Environmental factors and not genotype influence the plasma level of interleukin-1 receptor antagonist in normal individuals. Clin Exp Immunol (2004) 0.78
Dilemmas of low dosage glucocorticoid treatment in rheumatoid arthritis: considerations of timing. Ann Rheum Dis (1997) 0.77
Efficacy, safety and mechanism of action of modified-release prednisone in rheumatoid arthritis. Ther Adv Musculoskelet Dis (2012) 0.77
Neuroendocrine host factors and inflammatory disease susceptibility. Environ Health Perspect (1999) 0.76
Chronotherapy with low-dose modified-release prednisone for the management of rheumatoid arthritis: a review. Ther Clin Risk Manag (2016) 0.75
Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med (1968) 27.34
1958 Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis (1958) 24.41
A simple fluorimetric method for the estimation of free 11-hydroxycorticoids in human plasma. J Clin Pathol (1962) 18.80
Methods for cosinor-rhythmometry. Chronobiologia (1980) 5.59
Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med (1976) 5.16
Morning stiffness in rheumatoid arthritis. Ann Rheum Dis (1960) 1.68
Circadian variation in an immune response in man. Br Med J (1978) 1.62
Circadian variations in the signs and symptoms of rheumatoid arthritis and in the therapeutic effectiveness of flurbiprofen at different times of day. Br J Clin Pharmacol (1981) 1.31
Scientific assessment of the results of physical treatment--measurement of stiffness. Ann Phys Med (1966) 1.06
A simple enzyme immunoassay for the demonstration of rheumatoid factor. J Immunol Methods (1979) 1.01
Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med (2001) 7.41
"Lymphokines": non-antibody mediators of cellular immunity generated by lymphocyte activation. Nature (1969) 6.42
Genetic basis of rheumatoid disease: HLA antigens, disease manifestations, and toxic reactions to drugs. Br Med J (1978) 4.29
Rheumatoid arthritis in Greek and British patients. A comparative clinical, radiologic, and serologic study. Arthritis Rheum (1992) 3.92
An immunohistological analysis of lymphocyte subpopulations and their microenvironment in the synovial membranes of patients with rheumatoid arthritis using monoclonal antibodies. Clin Exp Immunol (1982) 3.05
Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum (2002) 2.75
The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum (1992) 2.68
E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis. Cancer Res (1991) 2.67
The sensitivity and specificity of reduced CD8 lymphocyte levels in the diagnosis of polymyalgia rheumatica/giant cell arteritis. Clin Exp Rheumatol (1994) 2.61
HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. Proc Natl Acad Sci U S A (1989) 2.60
A monoclonal antibody that detects a novel antigen on endothelial cells that is induced by tumor necrosis factor, IL-1, or lipopolysaccharide. J Immunol (1990) 2.55
HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N Engl J Med (1980) 2.52
Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis. Arthritis Rheum (1992) 2.31
Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum (1995) 2.25
Interleukin-2 reverses deficient cell-mediated immune responses in rheumatoid arthritis. Clin Exp Immunol (1984) 2.17
A role for purine metabolism in the immune response: Adenosine-deaminase activity and deoxyadenosine catabolism. Lancet (1978) 2.15
Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis (1993) 2.01
Cytokines and the chronic inflammation of rheumatic disease. I. The presence of interleukin-1 in synovial fluids. Clin Exp Immunol (1984) 1.95
D-Penicillamine induced toxicity in rheumatoid arthritis: the role of sulphoxidation status and HLA-DR3. J Rheumatol (1984) 1.69
Selective depletion and activation of CD8+ lymphocytes from peripheral blood of patients with polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis (1989) 1.68
IgA antibodies to Klebsiella pneumoniae in ankylosing spondylitis. Scand J Rheumatol (1983) 1.67
B lymphocyte alloantigens in the study of the genetic basis of rheumatoid arthritis. Ann Rheum Dis (1977) 1.65
Analysis of T cell subsets in the peripheral blood and synovial fluid of patients with rheumatoid arthritis by means of monoclonal antibodies. Ann Rheum Dis (1983) 1.64
Circadian variation in an immune response in man. Br Med J (1978) 1.62
The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis. J Immunol (2001) 1.62
Disease activity in rheumatoid arthritis: preliminary report of the Consensus Study Group of the European Workshop for Rheumatology Research. Clin Exp Rheumatol (1993) 1.57
Antibodies to intermediate filaments in polymyalgia rheumatica and giant cell arteritis: a sequential study. Ann Rheum Dis (1987) 1.54
The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol (1995) 1.49
Intramuscular gold decreases cytokine expression and macrophage numbers in the rheumatoid synovial membrane. Ann Rheum Dis (1994) 1.44
Pain treatment after thoracotomy: is it a special problem? Ann Thorac Surg (1997) 1.42
Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol (1990) 1.38
Influence of pregnancy on disease activity in a patient with palindromic rheumatism. J Rheumatol (1992) 1.38
ELISA assays for IgM and IgG rheumatoid factors. J Immunol Methods (1982) 1.37
Selective migration of the human helper-inducer memory T cell subset: confirmation by in vivo cellular kinetic studies. Eur J Immunol (1991) 1.34
Circadian variations in the signs and symptoms of rheumatoid arthritis and in the therapeutic effectiveness of flurbiprofen at different times of day. Br J Clin Pharmacol (1981) 1.31
Human pregnancy serum inhibits interleukin-2 production. Clin Exp Immunol (1984) 1.29
HLA-DRw4 and rheumatoid arthritis. Lancet (1979) 1.29
Circadian rhythmicity of delayed hypersensitivity to oxazolone in the rat. Clin Sci Mol Med (1978) 1.29
Strong primary selection for the Dw4 subtype of DR4 accounts for the HLA-DQw7 association with Felty's syndrome. Hum Immunol (1991) 1.27
Histocompatibility antigens in psoriasis, psoriatic arthropathy, and ankylosing spondylitis. Ann Rheum Dis (1983) 1.23
Evidence for the continuous recruitment and activation of T cells into the joints of patients with rheumatoid arthritis. Eur J Immunol (1994) 1.22
Genetic polymorphism of IL-12 p40 gene in immune-mediated disease. Genes Immun (2000) 1.21
Disease activity and pregnancy associated alpha 2-glycoprotein in rheumatoid arthritis during pregnancy. Br Med J (Clin Res Ed) (1983) 1.20
Intramuscular depot methylprednisolone induction of chrysotherapy in rheumatoid arthritis: a 24-week randomized controlled trial. Br J Rheumatol (1990) 1.20
Synovial T lymphocyte-specific immune response to Chlamydia trachomatis in Reiter's disease. Arthritis Rheum (1991) 1.19
The role of TNF-alpha in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology (Oxford) (2002) 1.19
Acute-phase proteins and serum immunoglobulins in ankylosing spondylitis. Ann Rheum Dis (1983) 1.19
Activated T lymphocytes of the synovial membrane in rheumatoid arthritis and other arthropathies. Scand J Immunol (1985) 1.19
The impact of the social network, stigma and empowerment on the quality of life in patients with schizophrenia. Eur Psychiatry (2010) 1.17
Interleukin-1 and interleukin-2 activity in chronic hepatitis B virus infection. Gastroenterology (1988) 1.15
Sequence analysis of HLA-DR4B1 subtypes: additional first domain variability is detected by oligonucleotide hybridization and nucleotide sequencing. Hum Immunol (1990) 1.14
In vivo analysis of disease modifying drug therapy activity in rheumatoid arthritis by sequential immunohistological analysis of synovial membrane interleukin 1 beta. J Rheumatol (1994) 1.13
Stromal cell-derived factor 1 (CXCL12) induces monocyte migration into human synovium transplanted onto SCID Mice. Arthritis Rheum (2002) 1.12
Response to glucocorticoid treatment in rheumatoid arthritis: in vitro cell mediated immune assay predicts in vivo responses. J Rheumatol (1991) 1.12
Domiciliary self-measurement in the rheumatoid arthritis and the demonstration of circadian rhythmicity. Ann Rheum Dis (1982) 1.11
Expression of HLA-DR, DQ and DP antigens and interleukin-2 receptor on synovial fluid T lymphocyte subsets in rheumatoid arthritis: evidence for "frustrated" activation. J Rheumatol (1987) 1.11
Resolution-associated molecular patterns (RAMP): RAMParts defending immunological homeostasis? Clin Exp Immunol (2011) 1.10
Control of rheumatoid arthritis by oral tolerance. Arthritis Rheum (2001) 1.09
Molecular cloning of major and minor allergens of Alternaria alternata and Cladosporium herbarum. Mol Immunol (1995) 1.09
Detection of renal allograft rejection by computer. Br Med J (Clin Res Ed) (1983) 1.08
Response of rheumatoid-synovial-fluid lymphocytes to non-specific mitogens. Lancet (1973) 1.07
Lymphocyte studies in rheumatoid arthritis. III. A comparative study of the responses of peripheral blood and synovial fluid lymphocytes to phytomitogens. Scand J Rheumatol (1979) 1.07
A combined immunohistological and histochemical analysis of lymphocyte and macrophage subpopulations in the rheumatoid nodule. Clin Exp Immunol (1984) 1.05
Detection of immune complexes in serum of patients with ankylosing spondylitis. Ann Rheum Dis (1978) 1.05
Possible effect of time on renal allograft rejection. Br Med J (1979) 1.05
Cytokines and the chronic inflammation of rheumatic disease. II. The presence of interleukin-2 in synovial fluids. Clin Exp Immunol (1984) 1.04
Binding of phytohaemagglutinin to serum substances and inhibition of lymphocyte transformation in Hodgkin's disease. Clin Exp Immunol (1976) 1.04
Hepatocellular uptake of ferritin in the rat. Br J Haematol (1974) 1.03
Autonomic insufficiency in uremia as a cause of hemodialysis-induced hypotension. N Engl J Med (1974) 1.03
Circulating immune complexes, serum immunoglobulins, and acute phase proteins in psoriasis and psoriatic arthritis. Ann Rheum Dis (1981) 1.03
Histocompatibility antigens in polymyalgia rheumatica and giant cell arteritis. J Rheumatol (1983) 1.02
Clotrimazole in rheumatoid arthritis. Ann Rheum Dis (1980) 1.02
HLA-DR4 restricted lymphocyte proliferation to a Mycobacterium tuberculosis extract in rheumatoid arthritis and healthy subjects. J Immunol (1988) 1.02
Action of chloroquine phosphate in rheumatoid arthritis. 1. Immunosuppressive effect. Ann Rheum Dis (1973) 1.02
Neuromyelitis optica (Devic's syndrome) and pulmonary tuberculosis. Neurology (1990) 1.02
Serum and secretory IgA immune response to Klebsiella pneumoniae in ankylosing spondylitis. Clin Rheumatol (1983) 1.01
Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients. Rheumatology (Oxford) (2000) 1.00
Dysregulation of the in vivo production of interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Pathogenetic implications. Arthritis Rheum (1995) 1.00
An improved method for sacro-iliac joint imaging: a study of normal subjects, patients with sacro-iliitis and patients with low back pain. Clin Radiol (1981) 0.99
Simultaneous ligation of CD5 and CD28 on resting T lymphocytes induces T cell activation in the absence of T cell receptor/CD3 occupancy. J Immunol (1993) 0.99
Changes in immune function in patients with rheumatoid arthritis following treatment with sodium aurothiomalate. Ann Rheum Dis (1981) 0.99
Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. Rheumatology (Oxford) (2002) 0.98
Does rheumatoid arthritis have a clinicopathological spectrum similar to that of leprosy? Ann Rheum Dis (1982) 0.98
Abnormal helper-inducer/suppressor-inducer T-cell subset distribution and T-cell activation status are common to all types of chronic synovitis. Scand J Immunol (1988) 0.98
Atopy and rheumatoid arthritis. Clin Allergy (1985) 0.98
Carcinoembryonic antigen in rheumatoid arthritis. Lancet (1974) 0.98
Time of day of prednisolone administration in rheumatoid arthritis. Ann Rheum Dis (1982) 0.98
A circadian study of corticosteroid suppression of delayed hypersensitivity. Int J Immunopharmacol (1979) 0.97
Defective polymorphonuclear leucocyte chemotaxis in rheumatoid arthritis associated with a serum inhibitor. Ann Rheum Dis (1980) 0.97
Abnormal lymphocyte reactivity to self-major histocompatibility antigens in rheumatoid arthritis. J Rheumatol (1987) 0.97
Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis. Clin Exp Immunol (1993) 0.97
Circadian rhythm of serum cytidine deaminase in patients with rheumatoid arthritis during rest and exercise. Ann Rheum Dis (1989) 0.97
Cutaneous lymphocyte antigen-positive T lymphocytes preferentially migrate to the skin but not to the joint in psoriatic arthritis. Arthritis Rheum (1996) 0.97
Data for long-term care planning. Application of a synthetic estimation technique. Res Aging (1988) 0.97
Functional assay of cytotoxic lymphocytes involved in antibody-mediated cytotoxicity in normal and rheumatoid subjects. Ann Rheum Dis (1977) 0.97
Lymphocytes are rhythmic: is this important? Br Med J (Clin Res Ed) (1984) 0.96